Skip to main content
Clinical Trials/DRKS00003203
DRKS00003203
Recruiting
Not Applicable

on-interventional study on the safety and efficacy of an Abraxane(R) mono therapy for the therapy of patients with metasasized breast cancer with special consideration of the toxicity profiles - Abraham study

OnkoDataMed GmbH !0 sites450 target enrollmentJuly 26, 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C50
Sponsor
OnkoDataMed GmbH !
Enrollment
450
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 26, 2011
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
OnkoDataMed GmbH !

Eligibility Criteria

Inclusion Criteria

  • Secured metastasized breast cancer with at least 1 metastasis (by means of RECIST or diffuse metastasis of the skeloton)
  • Gender: female
  • Alge: \=18 ýears
  • Signed patient informed consent
  • Therapy in a practice which is member of the BNGO
  • Adequate general condition \= 2 on the ECOG Scale
  • Adequate bone marrow reserves: number of neutrophiles \< 1,5 x 1E9 /L before start of the therapy

Exclusion Criteria

  • Pregnancy and lactation
  • Lack of compliance

Outcomes

Primary Outcomes

Not specified

Similar Trials